-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Decitabine in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Decitabine in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Decitabine in Metastatic Breast Cancer Drug Details: Decitabine (DW-1018) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – STK-012 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STK-012 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STK-012 in Non-Small Cell Lung Cancer Drug Details: STK-012 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KVA-12123 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Melanoma Drug Details: KVA-12123 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYNCAR-001 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYNCAR-001 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYNCAR-001 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYNCAR-001 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYNCAR-001 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYNCAR-001 in Non-Hodgkin Lymphoma Drug Details: SYNCAR-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYNCAR-001 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYNCAR-001 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYNCAR-001 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Non-Small Cell Lung Cancer Drug Details: AGENT-797...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – M-701 in Malignant Pleural Effusion
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - M-701 in Malignant Pleural Effusion report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. M-701 in Malignant Pleural Effusion Drug Details: M-701 is under development...
-
Product Insights
Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...